CYRX at a glance
Cryoport, Inc. (CYRX, SEC CIK 1124524) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Cryoport, Inc. (CYRX) reported revenue of $176.2 million (down 22.9% from FY2024) and net income of $78.3 million. Diluted EPS was $1.40.
- As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Cryoport, Inc. (CYRX) shares worth $304.9 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Sawicki Mark W on November 10, 2026 of 10,000 shares at $19.93 per share.
- In the last 90 days, CYRX insiders reported 0 open-market purchases ($0) and 2 open-market sales ($1.7M) on Form 4, a net sale of $1.7M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $176.2M
- −22.9% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$1.7M
- 13F holders
- 28 funds
- $304.9M · −2 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $50.2M, up 13.5% YoY from $44.2M
- Gross margin 47.5% vs 48.2% YoY, Life Sciences Products margin 43.6% vs 46.4%
- Best segment: Life Sciences Services revenue $28.6M, up 17.8%; BioStorage/BioServices up 25.1%
- Operating cash flow $10.1M, versus $(9.5)M YoY; capital expenditures and equipment purchases $24.3M
- Near-term outlook: operating losses expected amid expansion and technology investment; $186.2M notes repayment due December 2026
Risk Factors
- No material changes to risk factors from the 2025 Annual Report
- Carried-forward risk: unidentified or currently immaterial factors could adversely affect operations
- Business risk: existing annual-report risks could materially impair financial condition and results
- Regulatory risk: annual-report risks remain applicable, with no new quarterly developments disclosed
AI summary of the CYRX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Cryoport announced financial results for Q3 ended September 30, 2026
- Investors should review Exhibit 99.1 for reported revenue, profitability, cash flow and management outlook
Item EX-99.1: Item EX-99.1
- Q3 revenue $50.2M, up 14%, led by Life Sciences Services growth of 18% and BioStorage/BioServices growth of 25%
- Commercial cell and gene therapy revenue increased 20%, with support for 23 approved therapies and 788 clinical trials
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results released August 6, 2026, covering quarter ended June 30, 2026
- Detailed financial results and management commentary provided in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $49.0M, up 8% YoY; H1 revenue $96.8M, up 12%, led by Life Sciences Services growth
- Services revenue rose 15% to $28.0M, with BioStorage/BioServices up 25% to $5.6M
Item 5.07: Submission of Matters to a Vote of Security Holders
- All six director nominees re-elected through the 2027 annual meeting
- Deloitte & Touche ratified as auditor for fiscal 2026, with 47,014,962 votes for
AI summaries of CYRX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CYRX
Don't miss the next CYRX filing
- Alerts as it files. A push when CYRX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CYRX, by share count.
- Ask anything. An AI agent that reads every CYRX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Sawicki Mark W | Sell | Nov 10, 2026 | 10,000 | $19.93 |
| HANCOCK DANIEL M | Sell | Nov 9, 2026 | 74,379 | $20.21 |
| HANCOCK DANIEL M | M | Nov 9, 2026 | 20,549 | $7.00 |
| HANCOCK DANIEL M | M | Nov 9, 2026 | 20,549 | - |
| HANCOCK DANIEL M | M | Nov 9, 2026 | 30,000 | $9.73 |
| HANCOCK DANIEL M | M | Nov 9, 2026 | 23,830 | $12.65 |
| HANCOCK DANIEL M | M | Nov 9, 2026 | 23,830 | - |
| HANCOCK DANIEL M | M | Nov 9, 2026 | 30,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $228.4M | $176.2M |
| Gross Profit | - | $99.6M | $83.1M |
| Operating Income | - | -$130.9M | -$36.8M |
| Net Income | - | -$114.8M | $78.3M |
| Gross Margin | - | 43.6% | 47.1% |
| Op. Margin | - | -57.3% | -20.9% |
| Net Margin | - | -50.2% | 44.4% |
| Balance Sheet | |||
| Total Assets | $957.7M | $703.5M | $765.0M |
| Equity | $489.0M | $401.9M | $502.6M |
| ROE | - | -28.6% | 15.6% |
| Per Share | |||
| EPS | - | $-2.49 | $1.40 |
| Cash Flow | |||
| Operating CF | - | -$16.3M | -$8.6M |
| CapEx | - | $17.3M | $16.4M |
Source: XBRL data in Cryoport, Inc. (CYRX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CYRX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 28 | $304.9M |
| Q2 2026 | 30 | $268.6M |
| Q1 2026 | 29 | $160.9M |
| Q4 2025 | 28 | $194.4M |
| Q3 2025 | 28 | $196.7M |
| Q2 2025 | 27 | $142.4M |
| Q1 2025 | 23 | $96.2M |
| Q4 2024 | 19 | $84.1M |
- Citadel Advisors LLC+493.9K (+317%)
- AQR Capital Management+344.8K (+86%)
- Morgan Stanley+281.9K (+12%)
- Bank of America Corp+112.1K (+53%)
- Prudential Financial+91.2K (+100%)
- Millennium Management−288.9K (-17%)
- BlackRock−264.2K (-6%)
- Franklin Resources−130.4K (-66%)
- D.E. Shaw & Co−122.9K (-26%)
- Renaissance Technologies LLC−86.3K (-23%)
- Ameriprise Financial+66.9K
- FMR LLC (Fidelity)−20.9K
- Two Sigma Investments−14.3K
- Truist Financial−10.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 212 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CYRX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Aug 11, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 9, 2026 | - | - | |
| 8-K | Jun 9, 2026 | - | Analysis | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 4, 2026 | - | Analysis | - |
| 4 | Apr 23, 2026 | - | - | - |
| 4 | Apr 8, 2026 | - | - | - |
| 4 | Mar 25, 2026 | - | - | - |
| 4 | Mar 25, 2026 | - | - | - |
| 4 | Mar 25, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 16, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
CYRX SEC filings: frequently asked questions
Are CYRX insiders buying or selling?
In the last 90 days, Cryoport, Inc. (CYRX) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $1.7 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CYRX stock?
As of September 30, 2026, the largest Cryoport, Inc. (CYRX) holders among the 13F filers tracked by SignalX were BlackRock ($68.8 million), Morgan Stanley ($44.5 million), Vanguard Capital Management LLC ($37.4 million), Millennium Management ($25.0 million), State Street Corp ($18.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CYRX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Cryoport, Inc. (CYRX) reported revenue of $176.2 million (down 22.9% from FY2024) and net income of $78.3 million. Diluted EPS was $1.40. The figures come from the XBRL data in the 10-K.
What did CYRX report in its latest 8-K?
Cryoport, Inc. (CYRX) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Cryoport announced financial results for Q3 ended September 30, 2026.
What are the latest CYRX SEC filings?
Cryoport, Inc. (CYRX) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 12, 2026.
What is CYRX's SEC CIK number?
Cryoport, Inc. (CYRX)'s SEC Central Index Key (CIK) is 1124524. EDGAR lists every CYRX filing under that number.
Ask anything about CYRX
The research agent reads CYRX's filings, financials, insider trades and 13F holders, then answers with sources.